Overview
Portfolio
More
4BIO Capital
London, United Kingdom
4BIO Capital is a London‑based venture fund that invests exclusively in advanced therapy companies developing cell, gene, RNA‑based, targeted and microbiome treatments for high unmet medical needs. The firm focuses on ea...
Portfolio
23+
Employees
15+
Founded
2014
AUM
≈ $313.0M
Investment focus
Stages
Pre-Seed → Series A
Industries
BiotechnologyDigital HealthHealthcare Technology
Geographic scope
Global
Fund details
Funds
4BIO Ventures III LP
Vintage 2023 • $153.9
4BIO Ventures II LP
Vintage 2021 • $109.6
4BIO Advanced Therapies Fund ICAV
Vintage 2021 • $0.4
4BIO Advanced Therapies Long Equity Fund
Vintage 2021 • $0.4
4BIO Advanced Therapies Fund
Vintage 2019 • $49.5
Sources
4BIO Capital
4BIO Capital is a London‑based venture fund that invests exclusively in advanced therapy companies developing cell, gene, RNA‑based, targeted and microbiome treatments for high unmet medical needs. The firm focuses on early‑stage opportunities where scientific innovation can translate into curative or transformative therapies, leveraging its deep expertise and network in life sciences. By providing capital and strategic guidance, 4BIO aims to accelerate the path to market for breakthrough treatments that address critical health challenges.
Portfolio
23+
Employees
15+
Founded
2014
AUM
≈ $313.0M
Funds
4BIO Ventures III LP · Vintage 2023 • $153.9
4BIO Ventures II LP · Vintage 2021 • $109.6
4BIO Advanced Therapies Fund ICAV · Vintage 2021 • $0.4
4BIO Advanced Therapies Long Equity Fund · Vintage 2021 • $0.4
4BIO Advanced Therapies Fund · Vintage 2019 • $49.5
Stages
Pre-Seed → Series A
Industries
BiotechnologyDigital HealthHealthcare Technology
Geographic scope
Global
Sources
Showing 10 of 10 matched portfolio companies
Actithera develops next-generation radioligand therapies by linking radioactive isotopes to precisely designed molecules for targeted cancer treatment. Their proprietary chemistry ensures prolonged tumor retention and minimized off-target effects on healthy tissues. This approach aims to deliver effective treatment with fewer cycles, enhancing patient quality of life.
3+
200+Approximate amount of employees
Funding: $5.3M
Rough estimate of the amount of funding raised
Funding: $5.3M
Rough estimate of the amount of funding raised
Arbor secures lower electricity supply rates for consumers in deregulated energy markets without changing their utility provider. The service automatically finds and enrolls users in better supply plans, resulting in reduced monthly energy expenses. This process is managed seamlessly through an application, requiring no upfront cost or commitment from the customer.
Funding: $9.0M
Rough estimate of the amount of funding raised
Funding: $9.0M
Rough estimate of the amount of funding raised
Ascend is a finance automation platform designed for insurance retailers, brokers, MGAs, and carriers, utilizing administrative process automation and treasury management to enhance operational efficiency. By providing accurate revenue recognition and reducing back-office expenses, Ascend helps insurance businesses increase profitability and streamline financial operations.
Funding: $30.0M
Rough estimate of the amount of funding raised
Funding: $30.0M
Rough estimate of the amount of funding raised
Hornet Therapeutics develops IDO-1 inhibitors to target Epstein-Barr Virus (EBV) driven pathologies, including post-transplantation lymphoproliferative disease (PTLD). The company's precision engineering of immune cell metabolism aims to provide a therapeutic option for patients facing high mortality rates due to EBV-related complications.
Funding: $8.1M
Rough estimate of the amount of funding raised
Funding: $8.1M
Rough estimate of the amount of funding raised
LUCA Science develops targeted gene therapies to restore mitochondrial function in patients with mitochondrial diseases. The company focuses on providing effective treatment options in a field with limited alternatives, aiming to enhance patient outcomes and quality of life.
10+
500+Approximate amount of employees
Funding: $29.2M
Rough estimate of the amount of funding raised
Funding: $29.2M
Rough estimate of the amount of funding raised
March Biosciences develops CAR‑T cell therapies for hard‑to‑treat hematologic cancers, focusing on target unlocking without additional gene editing. The company emphasizes high cell quality and a streamlined manufacturing process to produce consistent, robust CAR‑T products. Its lead candidate, MB‑105, targets CD5 for relapsed/refractory T‑cell lymphoma.
10+
2K+Approximate amount of employees
Funding: $33.2M
Rough estimate of the amount of funding raised
Funding: $33.2M
Rough estimate of the amount of funding raised
Ray Therapeutics develops optogenetic gene therapies that utilize light-sensitive proteins to restore vision in patients with blinding diseases. By targeting specific retinal cells, these therapies aim to improve visual function in individuals suffering from conditions such as retinitis pigmentosa and age-related macular degeneration.
Funding: $106.0M
Rough estimate of the amount of funding raised
Funding: $106.0M
Rough estimate of the amount of funding raised
SparingVision is a clinical-stage biotechnology company developing mutation-independent genomic therapies for Inherited Retinal Diseases (IRDs), including Retinitis Pigmentosa, which affects millions globally. Their approach utilizes advanced gene therapy and genome editing techniques to provide treatment options for patients regardless of the specific genetic mutations causing their conditions.
Funding: $164.7M
Rough estimate of the amount of funding raised
Funding: $164.7M
Rough estimate of the amount of funding raised
Develops precision cancer therapies using a proprietary gene therapy platform that employs Synthetic Super-Enhancers (SSEs) to selectively activate therapeutic payloads in aggressive cancer cells. This approach targets tumors with minimal toxicity to healthy tissue, offering potential curative treatments and long-term immune protection against recurrence, starting with glioblastoma.
Funding: $19.1M
Rough estimate of the amount of funding raised
Funding: $19.1M
Rough estimate of the amount of funding raised
ViaNautis develops polyNaut®, a proprietary nanovesicle platform that utilizes advanced polymer materials and machine learning to deliver nucleic acid therapeutics with high precision to targeted tissues and cell types. This technology addresses the challenge of safely and effectively delivering genetic medicines, such as mRNA and siRNA, to treat previously untreatable diseases.
Funding: $28.5M
Rough estimate of the amount of funding raised
Funding: $28.5M
Rough estimate of the amount of funding raised
Showing 12 of 13 unmatched portfolio companies